Bristol-Myers Squibb (BMY) Balance Sheet

Click line-items for a historical chart and %

Current Assets:
Cash and cash equivalents	3.43B
Marketable securities	2.13B
Receivables	5.6B
Inventories	1.48B
Deferred income taxes
Prepaid expenses and other	565M
Total Current Assets	13.2B
Property, plant and equipment	4.79B
Goodwill	6.88B
Other intangible assets	1.38B
Deferred income taxes	3.53B
Marketable securities	3.04B
Other assets	918M
Total Assets	33.73B
Current Liabilities:
Short-term borrowings
Accounts payable	1.41B
Accrued expenses	4.96B
Deferred income	1.32B
Accrued rebates and returns
U.S. and foreign income taxes payable	312M
Dividends payable
Total Current Liabilities	9B
Pension, postretirement, and postemployment liabilities
Deferred income	567M
U.S. and foreign income taxes payable	905M
Other liabilities	1.64B
Long-term debt	5.84B
Total Liabilities	17.95B
Commitments and contingencies (Note 14)	0
Bristol-Myers Squibb Company Shareholders' Equity:
Preferred stock, $2 convertible series, par value $1 per share: Authorized 10 million shares; issued and outstanding 5,268 in 2011 and 5,269 in 2010, liquidation value of $50 per share	0
Common stock, par value of $0.10 per share: Authorized 4.5 billion shares; 2.2 billion issued in both 2011 and 2010	221M
Capital in excess of par value of stock	1.65B
Accumulated other comprehensive loss	-2.74B
Retained earnings	33.27B
Less cost of treasury stock - 500 million common shares in 2011 and 501 million in 2010	-16.8B
Total Bristol-Myers Squibb Company Shareholders' Equity	15.61B
Noncontrolling interest	168M
Total Equity	15.78B
Total Liabilities and Equity	33.73B

Entities mentioned with BMY